In a new study, researchers have identified a way to stop cells from dying, opening the door to developing treatments that ...

More than 50 years have passed since the discovery of fluoxetine, better known by its trade name Prozac. Together with the ...

Clinical-stage biopharmaceutical venture OmRx Oncology (OmRx) has commenced a randomised Phase II clinical trial for its oral ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Arialief for Neuropathy is a doctor-recommended joint support supplement made with natural, clinically backed ingredients ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

For those with existing neurological conditions, warm weather can cause these symptoms to worsen. Dr Steve, who works at Re: ...

On Wednesday, 2084 stocks advanced, 1871 declined and 151 remained unchanged on Bombay Stock Exchange with advance decline ...

Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard ...